ArticleBMC neurology2025
The potential role of IgG subclass in NF155-associated nodopathy for targeting therapy: a pediatric case report highlighting the efficacy of pulsed oral corticosteroids.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe autoimmune nodopathies are a distinct subgroup of immune-mediated polyneuropathies with characteristic clinical, pathophysiological, and electrophysiological features. IgG4 is the most frequently identified subclass and is typically associated with poor responsiveness to conventional therapies such as intravenous immunoglobulin and corticosteroids. However, emerging evidence highlights the relevance of non-IgG4 subclasses (e.g., IgG1), which may confer differential treatment responsiveness and prognostic implications. CASE PRESENTATION: We report a 15-year-old boy with subacute, progressive distal sensorimotor polyneuropathy who initially fulfilled the clinical and electrophysiological criteria for the distal variant of chronic inflammatory demyelinating polyneuropathy. Despite multiple courses of IVIG, the patient's symptoms worsened, prompting further investigation for nodal/paranodal antibodies. Serum testing revealed high-titre anti-NF155 antibodies of the IgG1 subclass, the IgG4 subclass was not detected. Due to the negative results of IgG4 we have decided not to start treatment with rituximab but with high-dose pulsed oral dexamethasone which resulted in marked clinical and electrophysiological improvement over a 36-month period, with excellent tolerance and no adverse effects.
conclusionPediatric patients presenting with demyelinating polyneuropathies unresponsive to intravenous immunoglobulins should be evaluated for autoimmune nodo-paranodopathies, including subclass-specific antibody profiling. In IgG1-NF155 associated autoimmune nodopathy, pulsed oral corticosteroids may represent an effective therapeutic option, whereas the response to intravenous immunoglobulin can be suboptimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.